Cargando…
Unraveling the mechanisms of IVIG immunotherapy in MIS-C
In The Journal of Clinical Investigation, Zhu et al.(1) report that intravenous immunoglobulin (IVIG) targets IL-1β(+) neutrophils to exert anti-inflammatory effects in multisystem inflammatory syndrome in children (MIS-C), a post-infectious inflammatory condition associated with COVID-19.
Autores principales: | Ganigara, Madhusudan, Sharma, Chetan, Bayry, Jagadeesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481087/ https://www.ncbi.nlm.nih.gov/pubmed/34608458 http://dx.doi.org/10.1016/j.xcrm.2021.100431 |
Ejemplares similares
-
Immunotherapy for MIS-C — IVIG, Glucocorticoids, and Biologics
por: DeBiasi, Roberta L.
Publicado: (2021) -
Obesity negatively impacts maintenance of antibody response to COVID-19 vaccines
por: Chauvin, Camille, et al.
Publicado: (2023) -
The Mystery of MIS-C Post-SARS-CoV-2 Infection
por: Brodsky, Nina N., et al.
Publicado: (2020) -
MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2021) -
Corrigendum: MIS-C Treatment: Is IVIG Always Necessary?
por: Licciardi, Francesco, et al.
Publicado: (2022)